This website uses cookies 🍪
We use cookies to ensure you get the best online experience. For more details, please see our Privacy and Cookie Policy. Read more.
Although the RSV virus may be unfamiliar to many, it is commonly known for causing illness in young children. However, older adults are also at risk, and in their case, the disease can be severe. RSV infects the lower respiratory tract, including the bronchi and lungs. Seasonal changes and specific virus characteristics can exacerbate symptoms. Early detection, symptom monitoring, and timely medical consultation at hospitals like Ramkhamhaeng Hospital are vital for risk reduction.
RSV is highly contagious and spreads mainly via respiratory droplets. Infection occurs through:
Elderly individuals and those with chronic illnesses are more vulnerable. Symptoms often resemble the common cold but may be more intense and longer-lasting, typically:
In adults, symptoms usually last under a week. However, people with chronic bronchitis, asthma, or COPD may experience prolonged symptoms lasting weeks or months.
Older adults, particularly those with weakened immune systems or pre-existing conditions, face a higher risk of complications, including:
Preventive care and infection control are essential for reducing these risks.
If symptoms are present and RSV is suspected, you can see a doctor. Diagnosis typically involves symptom assessment and nasal/throat swab testing. In severe cases, hospitalization may be required. Note that test sensitivity ranges from 53% to 96% and is available only at select hospitals.
RSV can recur even after recovery. It can be transmitted from children to adults and especially affects those with underlying conditions like lung or heart disease or weakened immunity, sometimes fatally.
There is now an effective RSV vaccine for both children and adults that helps prevent infection and reduce severity and complications. For older adults, it is recommended alongside other vaccines, such as the flu shot.
Early detection and medical attention reduce the risk of complications.
The Arexvy vaccine stimulates immunity to prevent Lower Respiratory Tract Disease (LRTD) caused by RSV. A single-dose vaccine can significantly reduce the risk of severe illness.
Timely prevention and treatment of RSV—especially through vaccination and hygiene practices—are essential in reducing disease severity, complications, and transmission among vulnerable groups.